Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | LSS | P48449 | 1/20 | 0.34 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | SORD | Q00796 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079502 | 0.91 | F10 (0.51) | F10SMN1; SMN2FASNPLGPRSS1 | |
| SCHEMBL6079244 | 0.90 | F10 (0.50) | F10LSSFASNPLGPRSS1 | |
| SCHEMBL6079662 | 0.90 | F10 (0.68) | F10 | |
| SCHEMBL6078682 | 0.87 | F10 (0.51) | F10SMN1; SMN2LSSFASNPLG | |
| SCHEMBL6079857 | 0.87 | F10 (0.51) | F10SMN1; SMN2 | |
| SCHEMBL6079877 | 0.84 | F10 (0.50) | F10SMN1; SMN2PLGPRSS1PRSS2 | |
| SCHEMBL6079604 | 0.83 | F10 (0.42) | F10SMN1; SMN2PLGPRSS1PRSS2 | |
| SCHEMBL6079446 | 0.82 | F10 (0.51) | F10SMN1; SMN2TRPV4 | |
| SCHEMBL6079429 | 0.82 | F10 (0.61) | F10SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6079428 | 0.81 | F10 (0.50) | F10SMN1; SMN2TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122662-B2 | Tricyclic compound having spiro union | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2006-10-17 | — | — | US | disclosed |
| US-20050148769-A1 | Tricyclic compound having spiro union | MOCHIDA PHARMACEUTICAL CO., LTD. | 2005-07-07 | — | — | US | disclosed |
| US-6858599-B2 | Inhibitor for activated blood coagulation factor X | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-02-22 | — | — | US | disclosed |
| EP-1191028-B1 | TRICYCLIC COMPOUNDS HAVING SPIRO UNION | MOCHIDA PHARM CO LTD (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-20040063716-A1 | Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20030045520-A1 | Tricyclic compound having spiro union | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | US | disclosed |
| EP-1191028-A1 | TRICYCLIC COMPOUNDS HAVING SPIRO UNION | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063716-A1 | Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds | VKORC1, CYP46A1, TFPI | F10 23/4885SMN1; SMN2 4813/4885LSS 78/4885 |
| US-20030045520-A1 | Tricyclic compound having spiro union | F2, TFPI, F11 | F10 7/4885SMN1; SMN2 4621/4885LSS 1635/4885 |
| US-20050148769-A1 | Tricyclic compound having spiro union | TFPI, F2, F12 | F10 7/4885SMN1; SMN2 4701/4885LSS 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.